## Ajanta Pharma Limited (AJANTPHARM) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Ajanta Pharma Limited (AJANTPHARM) is a pharmaceutical company listed on the National Stock Exchange of India (NSE) since May 29, 2000.  It operates within the Pharmaceuticals & Biotechnology sector, focusing on the manufacturing and marketing of pharmaceutical products.  While specific market positioning within the sector requires further research beyond the provided data, its presence on the NSE indicates a significant player in the Indian pharmaceutical market.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹2,819.90       |                                                                      |
| Percentage Change (PChange) | -1.94%          | Negative change indicates a recent price decline.                     |
| Pre-Open Activity          | Mixed           | Pre-open orders show some buying interest but limited volume (24 shares). |
| Week High                    | ₹3,485.00       | Significant high compared to the current price, suggesting recent volatility. |
| Week Low                     | ₹1,850.25       | Significant low compared to the current price, further indicating volatility. |
| VWAP                        | ₹2,877.70       | Volume Weighted Average Price slightly higher than the current price. |
| Sector PE                   | 41.05           | Industry average Price-to-Earnings ratio.                            |
| Symbol PE                   | 41.05           | Ajanta Pharma's Price-to-Earnings ratio, indicating valuation relative to earnings. |
| Delivery Percentage         | 52.83%          | Moderate delivery percentage; a significant portion of trades were delivery-based. |
| Market Depth                | Low             | Order book data shows low market depth, indicating limited liquidity.  |


**3. Financial Performance:**

The provided financial data shows a consistent profit after tax (PAT) and earnings per share (EPS) over the past five quarters, although the figures are unaudited for the most recent quarters.  However, it's crucial to note that all reported figures represent *profits*, not losses as the data initially suggests.  The data shows a positive trend in revenue and profit, but a detailed analysis requires further investigation into the financial statements.

| Quarter      | Revenue (₹) | Expenses (₹) | PAT (₹)  | EPS (₹) |
|--------------|-------------|-------------|---------|---------|
| Q2 FY25      | 116,925     | 86,005      | 23,498  | 18.75   |
| Q1 FY25      | 110,564     | 79,508      | 23,603  | 18.77   |
| Q4 FY24      | 95,975      | 73,381      | 16,269  | 12.92   |
| Q3 FY24      | 109,902     | 79,388      | 22,015  | 17.48   |
| Q2 FY24      | 99,734      | 70,684      | 21,236  | 16.87   |


**Key Financial Ratios:**  Further analysis is needed to calculate and interpret key ratios like Return on Equity (ROE), Debt-to-Equity ratio, and others to fully assess the financial health.  The provided data alone is insufficient for a comprehensive ratio analysis.

**4. Corporate Actions and Announcements:**

Ajanta Pharma has undertaken several corporate actions recently, including interim dividends and buybacks.  The frequency of these actions suggests a commitment to returning value to shareholders.  However, the impact of these actions on future stock performance needs further evaluation.  Recent announcements primarily relate to loss/duplicate share certificates and board meetings.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|--------------------|-----------|
| 30-Sep-2023  | 66.21                        | 33.79      | 0.00               | 100.00    |
| 31-Dec-2023  | 66.21                        | 33.79      | 0.00               | 100.00    |
| 31-Mar-2024  | 66.21                        | 33.79      | 0.00               | 100.00    |
| 30-Jun-2024  | 66.27                        | 33.73      | 0.00               | 100.00    |
| 30-Sep-2024  | 66.26                        | 33.74      | 0.00               | 100.00    |

Promoter holding remains relatively stable over the past year, indicating confidence in the company's prospects.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The high annualized volatility (37.25%) further confirms this.  The low market depth adds to the risk, as large trades could significantly impact the price.  The risk-reward profile is currently skewed towards higher risk due to volatility and low liquidity.

**7. Advantages of Buying the Stock:**

* **Consistent Profitability:**  The company has shown consistent profitability over the past five quarters (though unaudited for the most recent).
* **Regular Corporate Actions:**  Frequent dividend payouts and buybacks indicate a shareholder-friendly approach.
* **Stable Promoter Holding:**  High and stable promoter holding suggests confidence in the company's future.

**8. Disadvantages and Risks:**

* **High Volatility:**  The stock price is highly volatile, posing significant risk to short-term investors.
* **Low Liquidity:**  Low market depth makes it difficult to buy or sell large quantities without significantly impacting the price.
* **Limited Data:** The provided data is insufficient for a complete fundamental analysis.  More in-depth financial statements and industry benchmarks are needed.

**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Don't Buy.** The high volatility and low liquidity make short-term trading risky.  The recent price decline further discourages short-term investment.

* **Medium-Term (3 to 12 months): Hold (if you have stock).**  The company's consistent profitability and shareholder-friendly actions are positive long-term indicators. However, the high volatility needs to be considered.  Further research into the company's future prospects is recommended before initiating a new position.

* **Long-Term (1 year and beyond): Hold (if you have stock).**  The long-term outlook depends on the company's ability to maintain its profitability and navigate industry challenges.  Long-term investors should monitor the company's financial performance and industry trends closely.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* **Financial Health (out of 10): 7:** Consistent profitability, but limited data for a thorough assessment.
* **Market Performance (out of 10): 5:** Recent price decline and high volatility.
* **Volatility and Risk (out of 10): 4:** High volatility and low liquidity are significant risks.
* **Corporate Actions & Governance (out of 10): 8:**  Regular dividends and buybacks show a positive approach.
* **Shareholding Patterns (out of 10): 9:** Stable promoter holding indicates confidence.

**Analysis Score (out of 10): 7**

* **Data Utilization (out of 10): 8:** Most provided data was used, but some aspects required assumptions due to data limitations.
* **Analysis Clarity (out of 10): 7:** The analysis is clear, but further research is needed for a more comprehensive assessment.
* **Professional Formatting (out of 10): 9:** The report is well-structured and easy to read.


**11. Professional Recommendation Summary:**

Based on the available data, Ajanta Pharma shows signs of consistent profitability and a shareholder-friendly approach. However, the high volatility and low liquidity present significant risks, especially for short-term investors.  A "Don't Buy" recommendation is given for the short-term, while a "Hold" recommendation is suggested for medium and long-term horizons, contingent on further research and monitoring of the company's performance and market conditions.  Investors should conduct thorough due diligence before making any investment decisions.  The limited data provided necessitates further research to refine this analysis and improve the stock score.
